TG Therapeutics Inc (FRA:NKB2) Stock Price, Trades & News

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.68
Equity-to-Asset	0.38
Debt-to-Equity	1.29
Debt-to-EBITDA	5.02
Interest Coverage	5.41
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.69	Distress Grey Safe
Beneish M-Score	13.85	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	466.5
	3-Year FCF Growth Rate	50.8
	3-Year Book Growth Rate	118.5
	Future 3-5Y Total Revenue Growth Rate Estimate	36.01

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	43.94
	9-Day RSI	58.17
	14-Day RSI	63.46
	3-1 Month Momentum %	21.36
	6-1 Month Momentum %	38.48
	12-1 Month Momentum %	10.85

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.81
	Quick Ratio	5.12
	Cash Ratio	2.75
	Days Inventory	439.5
	Days Sales Outstanding	144.33

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2
	Shareholder Yield %	0.31

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	83.05
	Operating Margin %	21.35
	Net Margin %	65.95
	EBITDA Margin %	21.45
	FCF Margin %	-2.02
	OCF Margin %	-1.99
	ROE %	98.19
	ROA %	46.41
	ROIC %	24.72
	3-Year ROIIC %	43.95
	ROC (Joel Greenblatt) %	49.34
	ROCE %	18.08
	Years of Profitability over Past 10-Year	3
	Moat Score	3
	Tariff Resilience Score	8

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	18.64
	Forward PE Ratio	39.31
	PE Ratio without NRI	18.28
	Price-to-Owner-Earnings	34.13
	PS Ratio	12.22
	PB Ratio	14
	Price-to-Tangible-Book	14.01
	EV-to-EBIT	56.03
	EV-to-Forward-EBIT	31.46
	EV-to-EBITDA	55.93
	EV-to-Revenue	11.99
	EV-to-Forward-Revenue	9.03
	EV-to-FCF	-591.93
	Price-to-GF-Value	0.91
	Price-to-Graham-Number	3.37
	Price-to-Net-Current-Asset-Value	57.63
	Earnings Yield (Greenblatt) %	1.78
	FCF Yield %	-0.17

Financials (Next Earnings Date:2026-08-04 Est.)

Annual Quarterly TTM

FRA:NKB2's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

TG Therapeutics Inc Executives

Details

GF Value™: €50.8

FRA:NKB2

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with NKB2. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	601.863
	EPS (TTM) (€)	2.441
	Beta	1.0492
	3-Year Sharpe Ratio	0.45
	3-Year Sortino Ratio	0.78
	Volatility %	62.6
	14-Day RSI	63.46
	14-Day ATR (€)	1.009601
	20-Day SMA (€)	44.225
	12-1 Month Momentum %	10.85
	52-Week Range (€)	22.465 - 49.3
	Shares Outstanding (Mil)	153.08

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

TG Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

TG Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-03 08:30	In 122 days
Third quarter earnings results for 2026	2026-11-03	In 121 days
Second quarter earnings conference call for 2026	2026-08-04 08:30	In 31 days
Second quarter earnings results for 2026	2026-08-04	In 30 days
General meeting for 2026	2026-06-11 09:30	42.00 (+13.21%)
Goldman Sachs 47(th) Annual Healthcare Conference	2026-06-09 14:00	34.50 (+0.00%)
Jefferies Global Healthcare Conference	2026-06-03 11:40	31.80 (+0.00%)
First quarter earnings conference call for 2026	2026-05-06 08:30	30.30 (+0.00%)
First quarter earnings results for 2026	2026-05-06	30.30 (+0.00%)
Annual report for 2025	2026-02-27	24.81 (+0.00%)

Show

Entries

TG Therapeutics Inc Frequently Asked Questions

What is TG Therapeutics Inc(FRA:NKB2)'s stock price today?

The current price of FRA:NKB2 is €46.10. The 52 week high of FRA:NKB2 is €49.30 and 52 week low is €22.47.

When is next earnings date of TG Therapeutics Inc(FRA:NKB2)?

The next earnings date of TG Therapeutics Inc(FRA:NKB2) is 2026-08-04 Est..

Does TG Therapeutics Inc(FRA:NKB2) pay dividends? If so, how much?

TG Therapeutics Inc(FRA:NKB2) does not pay dividend.

Press Release

	Subject	Date
	Thinking about trading options or stock in TG Therapeutics, Microsoft, Eli Lilly And Co, Chevron, or Alcon?	2024-01-10
	INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against TG Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm	2023-09-27
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX	2023-09-13
	Thinking about buying stock in Nio Inc, Tupperware Brands, ZIM Integrated Shipping, Upstart Holdings, or TG Therapeutics?	2023-07-31
	Thinking about buying stock in Virgin Galactic Holdings, TG Therapeutics, Lucid Group, Ainos, or PainReform?	2023-07-14
	Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics?	2022-12-30
	Thinking about buying stock in Quotient, TAL Education, Core Scientific, TG Therapeutics, or Rivian Automotive?	2022-12-29
	TGTX SHAREHOLDER ALERT: Jakubowitz Law Reminds TG Therapeutics Shareholders of a Lead Plaintiff Deadline of September 16, 2022	2022-09-02
	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 16 Deadline in Securities Class Action - TGTX	2022-09-01
	TGTX LAWSUIT ALERT: Levi & Korsinsky Notifies TG Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline	2022-09-01

10/Page

Articles on TG Therapeutics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.